INNATE PHARMA SA-SPONS ADR (IPHA) Stock Earnings & Estimates
USA - NASDAQ:IPHA - US45781K2042 - ADR
1.86 USD
-0.04 (-2.11%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 49.58M 309.35% | 51.901M 4.68% | 12.622M -75.68% | 30.36M 140.53% | 28.411M -6.42% | 71.941M 153.22% | 81.489M 13.27% | 199.83M 145.22% | 255.4M 27.81% | 292.45M 14.51% | 307.72M 5.22% | |
| EBITDA YoY % growth | 28.98M 167.04% | -7.578M -126.15% | -49.581M -554.28% | 64.153M 229.39% | 76.427M 19.13% | 7.681M -89.95% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -16.425M 65.66% | -12.669M 22.87% | -51.575M -307.10% | 21.138M 140.98% | 24.466M 15.74% | -22.883M -193.53% | -35.366M -54.56% | 87.907M 348.56% | 138.63M 57.70% | 170.63M 23.08% | 180.29M 5.66% | |
| Operating Margin | -33.13% | -24.41% | -408.61% | 69.62% | 86.11% | -31.81% | -43.40% | 43.99% | 54.28% | 58.35% | 58.59% | |
| EPS YoY % growth | N/A 72.93% | N/A -169.82% | N/A 23.22% | 0.39 201.85% | 0.30 -23.23% | -0.18 -158.42% | N/A | N/A | N/A | N/A | N/A |
All data in EUR
| Q3 / 25 | Q4 / 25 | |
|---|---|---|
| EPS Q2Q % growth | -0.11 | -0.11 |
| Revenue Q2Q % growth | 1.98M | 2.172M -49.83% |
| EBITDA Q2Q % growth | N/A | N/A |
| EBIT Q2Q % growth | -12.857M | -12.665M 49.86% |
All data in EUR
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2021 Q2Q % growth | -0.59 -672.10% | % | ||
| Q4 2020 Q2Q % growth | -0.08 | % | ||
| Q3 2020 Q2Q % growth | -0.08 | % | ||
| Q2 2019 Q2Q % growth | 0.19 | 0.30 | -0.12 | -38.12% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 1.671M -79.85% | 4.909M | -3.238M | -65.96% |
| Q4 2024 Q2Q % growth | 4.329M -73.85% | % | ||
| Q2 2024 Q2Q % growth | 8.293M -76.54% | % | ||
| Q4 2023 Q2Q % growth | 16.557M 99.27% | % | ||
| Q2 2023 Q2Q % growth | 35.344M -14.36% | % | ||
| Q4 2022 Q2Q % growth | 8.309M 118.20% | % | ||
| Q2 2022 Q2Q % growth | 41.271M 397.00% | % | ||
| Q4 2021 Q2Q % growth | 3.808M -85.53% | % | ||
| Q2 2021 Q2Q % growth | 8.304M -72.17% | % | ||
| Q4 2020 Q2Q % growth | 26.31M 51.33% | 27.379M | -1.069M | -3.90% |
| Q3 2020 Q2Q % growth | 22.86% | 27.379M | % | |
| Q2 2020 Q2Q % growth | 29.84M -42.16% | % | ||
| Q4 2019 Q2Q % growth | 17.386M | 22.285M | -4.899M | -21.98% |
| Q2 2019 Q2Q % growth | 51.588M | 58.735M | -7.147M | -12.17% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | N/A | 0% | 401.07% |
| Revenue | 0% | N/A | 0% | -60.14% |